Although it is well known that anti-angiogenesis therapies disrupt the tumour vasculature, the D2R agonist-mediated anti-angiogenesis process can also transiently “normalize” the abnormal structure and function of tumour vasculature to make it more efficient for oxygen and drug delivery [70], which was clearly seen in our preclinical models (Figs. 1–4). Here, DRD2 is linked to neoplasm.